Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension that causes high blood pressure in the small arteries of the lungs. It is a serious condition that can impair blood flow, ...

Earlier studies often prioritized one scale at the expense of the other and, because this, missed critical connections. In pulmonary hypertension, however, this partnership turns lethal. PAAFs start ...

Background: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension (PPH). Recently, fenfluramine appetite suppressants became widely ...

"Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis" has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for ...

"Pulmonary hypertension usually affects people aged 30 to 60. Its early signs and symptoms can mimic those of various other medical conditions, making early detection challenging," explains Dr Garde.

Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension that causes high blood pressure in the small arteries of the lungs. It is a serious condition that can impair blood flow ...

The importance of hypertension of the pulmonary circulation in the natural history of mitral stenosis has been appreciated for many years. Many of the classic signs of this type of cardiac disease ...

Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension. It occurs because progressive vascular changes cause the small pulmonary arteries to narrow. As a result ...

Background Pulmonary hypertension (PHT) lacks community prevalence and outcome data. Objective To characterise minimum ‘indicative’ prevalences and mortality data for all forms of PHT in a selected ...

Systemic lupus erythematosus is associated with an increased risk for pulmonary manifestations, including interstitial lung disease and pulmonary hypertension. Systemic lupus erythematosus (SLE) may ...

Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension.